Beta Bionics Inc. (BBNX)
NASDAQ: BBNXHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BBNX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $726.34M
- EPS (TTM)
- -$1.83
- Dividend yield
- None
- 52-week range
- 8.80 – 32.71
- Day range
- 12.92 – 13.85
- Volume / Avg
- 960.30K / 1.21M
- Beta
- —
- Shares outstanding
- 54.37M
52-week range
BBNX stock today
Shares of Beta Bionics (BBNX) finished higher on Nov 20 at $13.36, a gain of 0.30% or $0.04 per share, versus the S&P 500's 3.70% decline. At this level, BBNX sits near the bottom of its 52-week range of $8.80 to $32.71: 59.2% below the high, set on Nov 26, 2025 and 51.8% above the low. BBNX is down 56.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.5%.
Beta Bionics has posted a net loss over the last twelve months (EPS of -$1.83), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Beta Bionics
Company profileBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Sean T. Saint PE
- Headquarters
- Irvine, CA
- Employees
- 420
- IPO year
- 2025
- Website
- betabionics.com
Financial highlights
Full financialsIn fiscal 2025, Beta Bionics generated $100.3 million in revenue, up 53.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Beta Bionics reported a net loss of $73.2 million, compared with a loss of $54.8 million a year earlier. Gross margin was 55.4% (up from 55.1%) and operating margin -71.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $100.25M | $65.12M | $11.99M |
| Growth | +53.94% | +442.93% | — |
| Net income | $-73.20M | $-54.76M | $-44.10M |
| EPS (diluted) | $-1.81 | $-8.60 | $-8.31 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$25.10+87.87%
- Strong buy 2
- Buy 9
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $-0.52 vs $-0.53
- Surprise
- +1.89%
BBNX news
All BBNX news- BBNX & SENS Launch Eversense 365 Integration With iLet Bionic PancreasNasdaqSENS, BBNX, ISRG, GKOS
- Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas IntegrationGlobeNewswireBBNX, SENS
- Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas IntegrationGlobeNewswireSENS, BBNX
- Beta Bio: 3 Key Takeaways for Long-Term InvestorsNasdaqBBNX, LEN.B
- BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud LawsuitPR Newswire
- Beta Bionics Announces Participation at Upcoming Investor ConferencesGlobeNewswire
- BBNX SHAREHOLDER NOTICE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class ActionPR Newswire
- BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud LawsuitPR Newswire
Beta Bionics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VVVVvVARDIS Holding AG Class A | 14.55 | -3.00% | $770.91M | vs BBNX |
| BVSBioventus Inc. Class A | 9.88 | -0.70% | $676.53M | vs BBNX |
| DCTHDelcath Systems Inc. | 18.79 | -2.34% | $653.67M | vs BBNX |
| KIDSOrthoPediatrics Corp. | 31.74 | -2.37% | $828.75M | vs BBNX |
| TCMDTactile Systems Technology Inc. | 25.60 | -1.50% | $573.48M | vs BBNX |
| SGHTSight Sciences Inc. | 10.18 | -4.14% | $565.79M | vs BBNX |
| AORTArtivion Inc. | 18.16 | -2.00% | $886.02M | vs BBNX |
| RCELAvita Medical Inc. | 15.62 | -2.31% | $494.96M | vs BBNX |
Indexes, lists and sector
Beta Bionics stock FAQ
What is Beta Bionics's stock price today?
BBNX last traded at $13.36 as of Nov 20, 4:00 PM EST, up 0.30% on the day. Prices are delayed at least 15 minutes.
Who is Beta Bionics's CEO?
Mr. Sean T. Saint PE is the chief executive officer of Beta Bionics Inc., which has about 420 employees.
What is the BBNX 52-week high?
The 52-week high for BBNX is $32.71 and the 52-week low is $8.80. The stock is currently 59.2% below its high.